Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

CTNM Revenue & Earnings

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported revenue of $0 and net income of $-59,978,000 for FY 2025, with a net profit margin of 0%. Revenue represents total sales while net income is the profit remaining after all expenses. The relationship between them reflects overall profitability.